Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Starts Phase I Trial that Combines its PD-L1 with Bayer's Stivarga®

publication date: Jan 28, 2020

CStone Pharma of Suzhou has dosed the first patient in an Australian clinical trial that combines its PD-L1 inhibitor with Bayer's Stivarga® (regorafenib), an oral multi-kinase inhibitor. CStone already has eight clinical trials of CS1001 underway, including four China Phase III studies. Bayer's regorafenib, which blocks protein kinases including VEGFR, FGFR, and CSF1R, is approved globally for metastatic colorectal cancer, metastatic gastrointestinal stromal tumors and advanced hepatocellular carcinoma. In May 2019, CStone and Bayer announced a global clinical CS1001-regorafenib collaboration with CStone responsible for conducting the tests. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.